Compare ABCL & UVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABCL | UVV |
|---|---|---|
| Founded | 2012 | 1886 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2020 | 1994 |
| Metric | ABCL | UVV |
|---|---|---|
| Price | $9.44 | $47.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.40 | N/A |
| AVG Volume (30 Days) | ★ 6.1M | 247.8K |
| Earning Date | 05-11-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 6.25% |
| EPS Growth | ★ 10.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $75,128,000.00 | ★ $2,885,078,000.00 |
| Revenue This Year | N/A | $0.67 |
| Revenue Next Year | $21.85 | $0.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 160.56 | N/A |
| 52 Week Low | $2.75 | $46.96 |
| 52 Week High | $10.01 | $59.38 |
| Indicator | ABCL | UVV |
|---|---|---|
| Relative Strength Index (RSI) | 77.04 | 28.98 |
| Support Level | $3.38 | N/A |
| Resistance Level | N/A | $54.26 |
| Average True Range (ATR) | 0.51 | 1.36 |
| MACD | 0.29 | -0.50 |
| Stochastic Oscillator | 87.97 | 5.45 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Universal Corp is an international leaf tobacco supplier. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Tobacco Operations segment involves procuring and processing flue-cured, burley, dark air-cured, and oriental leaf tobacco for manufacturers of consumer tobacco products and performing related services. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, the Philippines, Germany, and Other Countries, with the majority of revenue from the USA.